SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 936,747 shares of the company’s stock after selling 42,847 shares during the period. Victory Capital Management Inc. owned about 1.50% of SpringWorks Therapeutics worth $26,725,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of SpringWorks Therapeutics by 22.6% during the 2nd quarter. FMR LLC now owns 7,412,040 shares of the company’s stock worth $182,484,000 after purchasing an additional 1,365,831 shares during the last quarter. High Net Worth Advisory Group LLC boosted its holdings in shares of SpringWorks Therapeutics by 100.0% during the 3rd quarter. High Net Worth Advisory Group LLC now owns 1,000 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of SpringWorks Therapeutics during the 2nd quarter worth approximately $1,678,000. Rafferty Asset Management LLC raised its position in shares of SpringWorks Therapeutics by 92.3% during the 2nd quarter. Rafferty Asset Management LLC now owns 174,704 shares of the company’s stock valued at $4,301,000 after buying an additional 83,875 shares during the period. Finally, Strs Ohio raised its position in shares of SpringWorks Therapeutics by 6.1% during the 2nd quarter. Strs Ohio now owns 15,600 shares of the company’s stock valued at $384,000 after buying an additional 900 shares during the period.

Analysts Set New Price Targets

SWTX has been the topic of several analyst reports. HC Wainwright reduced their price target on shares of SpringWorks Therapeutics from $103.00 to $99.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. The Goldman Sachs Group reduced their price target on shares of SpringWorks Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, October 21st. Bank of America initiated coverage on shares of SpringWorks Therapeutics in a research report on Thursday, December 1st. They set a “buy” rating and a $45.00 price target on the stock. Finally, Wedbush set a $45.00 price target on shares of SpringWorks Therapeutics in a research report on Thursday, November 24th.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX opened at $27.55 on Tuesday. SpringWorks Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $65.92. The business’s 50 day moving average is $25.19 and its two-hundred day moving average is $26.73.

SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.06). Sell-side analysts expect that SpringWorks Therapeutics, Inc. will post -5.23 EPS for the current fiscal year.

SpringWorks Therapeutics Company Profile

(Get Rating)

SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.